Cancer Approval Standards, FDA Reputation At Stake With Avastin Hearing, NEJM Authors Say
This article was originally published in The Pink Sheet Daily
Executive Summary
In separate perspective pieces in the New England Journal of Medicine, Boston academics criticize the 2008 approval of bevacizumab's breast cancer claim based on progression-free survival and warn the agency's credibility will be undermined if the claim is not withdrawn.
You may also be interested in...
CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing
Proposed study of bevacizumab in first-line metastatic breast cancer is unlikely to substantiate the magnitude of progression-free survival benefit seen in the E2100 trial, Division of Biologic Oncology Products Director Patricia Keegan says.
CDER Attacks Genentech's Plans For New Confirmatory Trial At Avastin Hearing
Proposed study of bevacizumab in first-line metastatic breast cancer is unlikely to substantiate the magnitude of progression-free survival benefit seen in the E2100 trial, Division of Biologic Oncology Products Director Patricia Keegan says.
Less Than Half Of ODAC Members Will Participate In Avastin Hearing
The "jury" for FDA's June 28-29 hearing on Avastin's breast cancer indication will consist of only six voting participants, five of whom previously called for the claim's withdrawal.